FDA Approved: IMBRUVICA — Supplemental Application (Pharmacyclics LLC)

View source ↗

Summary

The FDA approved a supplemental application for IMBRUVICA (ibrutinib) submitted by Pharmacyclics LLC.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Lymphocytic Leukemia
• Graft-versus-host Disease
• Mantle Cell Lymphoma
• Small Lymphocytic Lymphoma
• Waldenström Macroglobulinemia

Drugs mentioned

• IMBRUVICA (IBRUTINIB)

Snippet

SUPPL AP for IMBRUVICA (IBRUTINIB)